[1] | Kato, G.J., Piel, F.B., Reid, C.D., et al. (2018). Sickle cell disease. Nat. Rev. Dis. Primers 4: 18010. https://doi.org/10.1038/nrdp.2018.10. |
[2] | Origa, R. (2017). β-Thalassemia. Genet. Med. 19: 609-619. https://doi.org/10.1038/gim.2016.173. |
[3] | Frangoul, H., Altshuler, D., Cappellini, M.D., et al. (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N. Engl. J. Med. 384: 252-260. https://doi.org/10.1056/NEJMoa2031054. |
[4] |
(2023). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. (FDA News release). |
[5] |
(2024). CASGEVY (exagamglogene autotemcel) suspension for intravenous infusion. |
Rao S., Yao Y., Huo W., et al., (2024). Revolutionizing genetic disease treatment: The case of exagamglogene autotemcel. The Innovation 5(3), 100619. https://doi.org/10.1016/j.xinn.2024.100619 |
Ex vivo genome editing for the treatment of SCD